Talphera (TLPH) Cash from Financing Activities (2010 - 2026)
Talphera (TLPH) posted quarterly Cash from Financing Activities of $4.0 million for Q1 2026, up 80960.0% year-over-year from N/an in Q1 2025, and up 188.17% quarter-over-quarter from $1.4 million in Q4 2025.
Talphera (TLPH) Cash from Financing Activities (2010 - 2026) Analysis & Trends
Talphera's Cash from Financing Activities history runs 17 years deep, the most recent figure standing at $4.0 million for Q1 2026.
- In Q1 2026, Cash from Financing Activities rose 80960.0% year-over-year to $4.0 million; the TTM figure through Mar 2026 stood at $26.8 million (up 107052.0% YoY), while the FY2025 annual figure was $22.7 million, up 88.81% from the prior year.
- Cash from Financing Activities for Q1 2026 stood at $4.0 million, up from $1.4 million in the prior quarter.
- The five-year high for Cash from Financing Activities was $17.0 million in Q3 2025, with the low at -$3.3 million in Q2 2023.
- The 5-year median for Cash from Financing Activities is $30000.0 (2024), against an average of $2.8 million.
- The sharpest annual moves came in 2022 and 2026: Cash from Financing Activities tumbled 106.09% in 2022, then surged 80960.0% in 2026.
- Talphera's Cash from Financing Activities stood at $5.3 million in 2022, then slumped by 101.28% to -$68000.0 in 2023, then surged by 144.12% to $30000.0 in 2024, then soared by 4576.67% to $1.4 million in 2025, then jumped by 188.17% to $4.0 million in 2026.
- Business Quant data shows TLPH's Cash from Financing Activities at $4.0 million in Q1 2026, $1.4 million in Q4 2025, and $17.0 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.83 Bn | 42.86 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 42.87 Bn | 39.22 Bn | 2.15 Bn | -1.00 Mn |
| 3 | Zoetis | 31.41 Bn | 29.73 Bn | 1.05 Bn | -813.00 Mn |
| 4 | Takeda Pharmaceutical | 28.55 Bn | 22.75 Bn | 5.10 Bn | -1.13 Bn |
| 5 | United Therapeutics | 22.08 Bn | 19.42 Bn | 683.80 Mn | 122.40 Mn |
| 6 | Viatris | 18.73 Bn | 17.84 Bn | 1.46 Bn | -1.24 Bn |
| 7 | Neurocrine Biosciences | 15.44 Bn | 15.05 Bn | 935.80 Mn | 63.40 Mn |
| 8 | Elanco Animal Health | 11.75 Bn | 11.22 Bn | 798.00 Mn | -74.00 Mn |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.94 Bn | - | - |
| 10 | Talphera | 90.63 Mn | 90.63 Mn | - | -261,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -261,000.00 |
| Jun 30, 2026 | -261,000.00 |
| Mar 31, 2026 | 4.04 Mn |
| Mar 31, 2026 | 4.04 Mn |
| Dec 31, 2025 | 1.40 Mn |
| Dec 31, 2025 | 1.40 Mn |
| Sep 30, 2025 | 16.99 Mn |
| Sep 30, 2025 | 16.99 Mn |
| Jun 30, 2025 | 4.35 Mn |
| Jun 30, 2025 | 4.35 Mn |
| Mar 31, 2025 | -5,000.00 |
| Mar 31, 2025 | -5,000.00 |
| Sep 30, 2024 | 30,000.00 |
| Sep 30, 2024 | 30,000.00 |
| Mar 31, 2024 | 12.01 Mn |
| Mar 31, 2024 | 12.01 Mn |
| Dec 31, 2023 | -68,000.00 |
| Dec 31, 2023 | -68,000.00 |
| Sep 30, 2023 | 8.94 Mn |
| Sep 30, 2023 | 8.94 Mn |